A clinical formulation indicated for Skin Care. Application assists with the localized immune response to minimize actinic keratosis and superficial basal cell carcinoma.
An immune response modifier developed to manage precancerous skin lesions and designed to alleviate external warts by supporting the body's natural defenses.
Mechanism of Action
It stimulates the immune system by activating toll-like receptor 7. This triggers the production of cytokines like interferon, which attack viruses and cancer cells.
Route of Administration
Topical
Onset Time
Several weeks
Duration
Variable
Contraindications
Broken or bleeding skin, Allergy to imiquimod
Severe Adverse Events
Severe skin ulceration, Hypopigmentation (permanent), Severe allergic reaction
Information for Imiquimod is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
